Literature DB >> 3587324

Mexiletine and caffeine elimination.

R Joeres, E Richter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3587324     DOI： 10.1056/NEJM198707093170214

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Authors:  Kiyomi Ito; Koji Chiba; Masato Horikawa; Michi Ishigami; Naomi Mizuno; Jun Aoki; Yasumasa Gotoh; Takafumi Iwatsubo; Shin-ichi Kanamitsu; Motohiro Kato; Iichiro Kawahara; Kayoko Niinuma; Akiko Nishino; Norihito Sato; Yuko Tsukamoto; Kaoru Ueda; Tomoo Itoh; Yuichi Sugiyama
Journal:  AAPS PharmSci       Date:  2002

2.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 3.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

4.  4-quinolones inhibit biotransformation of caffeine.

Authors:  S Harder; A H Staib; C Beer; A Papenburg; W Stille; P M Shah
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.